Skip to main
MGTX
MGTX logo

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings PLC is expanding its financial runway into 2027, supported by the anticipated closing of the Hologen deal, indicating strong liquidity and operational stability. The company is focused on innovative one-time functional cures in ophthalmology, with Phase II trial results showing positive outcomes, including statistically significant improvements in visual acuity and patient-reported outcomes. Additionally, with a Biologics License Application (BLA) filing expected in 2026 and promising data from pediatric cases, MeiraGTx demonstrates potential for strong future growth in the gene therapy market.

Bears say

MeiraGTx Holdings PLC faces significant risks related to regulatory approval for its pipeline products, as any delays or complexity in the approval process could lead to substantial downward revisions in risk-adjusted projections and price targets. The company's financial performance is concerning, as it reported a net loss of $148 million, translating to an EPS of ($2.12), which exceeds prior loss estimates. Additionally, challenges related to the pricing of its gene therapies in comparison to existing orphan drugs and a higher likelihood of manufacturing setbacks present further uncertainties that could negatively impact financial forecasts.

MGTX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Buy based on their latest research and market trends.

According to 6 analysts, MGTX has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.